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Background: Participation in coronary heart disease (CHD) secondary prevention programs is low. Telephone-
delivered CHD secondary prevention programs may overcome the treatment gap. The telephone-based health
coaching ProActive Heart trial intervention has previously been shown to be effective for improving health-related
quality of life, physical activity, body mass index, diet, alcohol intake and anxiety. As a secondary aim, the current
study evaluated the cost-effectiveness of the ProActive Heart intervention compared to usual care.
Methods: 430 adult myocardial infarction patients were randomised to a six-month CHD secondary prevention ‘health
coaching’ intervention or ‘usual care’ control group. Primary outcome variables were health-related quality of life
(SF-36) and physical activity (Active Australia Survey). Data were collected at baseline, six-months (post-intervention)
and 12 months (six-months post-intervention completion) for longer term effects. Cost-effectiveness data [health utility
(SF-6D) and health care utilisation] were collected using self-reported (general practitioner, specialist, other health
professionals, health services, and medication) and claims data (hospitalisation rates). Intervention effects are presented
as mean differences (95% CI), p-value.
Results: Improvements in health status (SF-6D) were observed in both groups, with no significant difference between
the groups at six [0.012 (−0.016, 0.041), p = 0.372] or 12 months [0.011 (−0.028, 0.051) p = 0.738]. Patients in the health
coaching group were significantly more likely to be admitted to hospital due to causes unrelated to cardiovascular
disease (p = 0.042). The overall cost for the health coaching group was higher ($10,574 vs. $8,534, p = 0.021), mainly
due to higher hospitalisation (both CHD and non-CHD) costs ($6,841 vs. $4,984, p = 0.036). The incremental cost-
effectiveness ratio was $85,423 per QALY.
Conclusions: There was no intervention effect measured using the SF-36/SF-6D and ProActive Heart resulted in
significantly increased costs. The cost per QALY gained from ProActive Heart was high and above acceptable limits
compared to usual care.Background
Coronary heart disease (CHD) is a major cause of mor-
bidity, mortality and economic burden in Australia and
the rest of the developed world [1]. Secondary preven-
tion programs, with a focus on risk factor management,
have been shown to play a pivotal role in the treatment
and management of those affected by CHD. The clinical* Correspondence: e.turkstra@griffith.edu.au
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reproduction in any medium, provided the orbenefits of secondary prevention / cardiac rehabilitation
programs include decreased total cardiac mortality
(26%), improved health-related quality of life (HRQoL),
and lower rates of rehospitalisation [2-4]. As such,
guidelines recommend that all persons with CHD par-
ticipate in secondary prevention programs [5,6].
Telephone-delivered interventions are one option to de-
liver cardiac rehabilitation [7-9] and there is a large body
of literature on home-based and telehealth programs for
patients with heart failure [10] or diabetes [11]. While
there is a growing body of evidence demonstrating thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patients there is a paucity of evidence on the cost-
effectiveness of telephone-based interventions [12]. A re-
cent systematic review by Goode et al. (2012) identified
two publications on the cost-effectiveness of telephone-
delivered interventions using physical activity and dietary
behaviour change [12]. Both publications supported the
cost-effectiveness of telephone-delivered interventions
[13,14], albeit the interventions and populations were dif-
ferent from that in the ProActive Heart study. In the
randomised controlled trial reported by Graves et al.
(2009) the trial-based intervention was not compared with
the usual care (UC) group but used a theoretical UC
group instead [14]. A systematic review that included costs
as a key outcome identified 28 tele-rehabilitation studies.
That review reported that there was preliminary evidence
around potential cost-savings to the health system and
concluded that “high-quality evidence regarding impact
on resource allocation and costs is still needed to support
clinical and policy decision-making” [15].
The ProActive Heart trial was a novel telephone-
delivered secondary prevention program. The primary
aim of that study was to achieve significantly greater im-
provements in HRQoL and physical activity for a health
coaching (HC) intervention versus UC patients. The effi-
cacy outcomes have been published previously [16,17];
in summary, significant intervention effects were ob-
served for mental HRQoL (p = 0.02), social functioning
(p = 0.04) and role-emotional (p = 0.03) subscales com-
pared with UC. Intervention participants were also more
likely to meet recommended levels of physical activity
(p = 0.02), body mass index or BMI (p = 0.05), vegetable
intake (p = 0.04), and alcohol consumption (p = 0.05)
[16]. A significant intervention effect was also observed
for anxiety compared with UC (p = 0.04) [17]. A secon-
dary aim of the study was to examine the cost-
effectiveness of the ProActive Heart intervention, which
we report here.
Methods
The study design, aims and recruitment procedures have
been published previously [18]. In brief, patients with a
recent myocardial infarction (MI) were randomised to
the HC or UC group. Participants in both groups com-
pleted assessments at baseline, post-intervention or six-
months follow-up, and at 12-months follow-up. The
cost-effectiveness results are based on six-months of
follow-up data as this was the primary end point. Ethics
approval was received from Human Research Ethics
Committees of The Prince Charles Hospital (EC2738),
the Royal Brisbane and Women’s Hospital (2007/049),
and Monash University (2007/0584MC). We recruited
430 adult MI patients over a 14 month period (December
2007 to January 2009) from two large metropolitanhospitals in Brisbane, Australia (Royal Brisbane and
Women’s, and The Prince Charles Hospitals).
Study conditions
The intervention commenced within the first two weeks
of discharge. UC participants received existing written
educational resources. Over a six-month period, HC par-
ticipants received 10 × 30 minute scripted telephone HC
sessions from a qualified health professional or ‘health
coach’. Details of the telephone HC sessions have been
provided previously [18].
Measurement
Clinical data were collected at baseline from hospital
medical records. Socio-demographic data was self-
reported at baseline and additional data were collected
at baseline, six and 12 months by computer assisted tele-
phone interview (CATI).
Cost-effectiveness
A cost-effectiveness analysis of the costs and outcomes for
patients in the intervention and control groups was
conducted from the perspective of health care costs to the
Australian government. The primary health outcome for
the cost-effectiveness analyses was quality-adjusted life
years (QALYs). These were calculated for both groups
using HRQoL scores from the SF-36 [19] and converted
to utility scores using the SF-6D, using UK weights [20].
Resource use and costs
Details of the resource use and costs are presented in
the Web Appendix Additional file 1: Table S1. In sum-
mary, most of the resource utilisation was based on self-
reporting [general practitioner (GP) visits, specialist
visits, other health professionals visits, and medication].
Hospital resource use and inpatient costs using AR-
DRGs were sourced from Queensland Health Admitted
Patient Data Collection which includes all public hos-
pital separations in Queensland. Hospitalisation was
categorised by cardiovascular hospitalisations (including
MI, angina and chronic heart failure) and other hos-
pitalisations. The GP visits were validated from a ran-
domised sub-sample of 10% of patient records and
provider surveys, which indicated underreporting. To
adjust for this underreporting a correlation coefficient
was applied to the patient reported GP visits to estimate
the actual visits (See Additional file 1).
National average costs for each item of resource use
were applied (Additional file 1). All costs are reported in
2008 Australian dollars.
Data analysis
To assess differences in baseline characteristics between
HC and UC groups Pearson chi-squared tests were used
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continuous data. As there was missing data for the SF-6D
at six months (HC n = 73, UC n = 62 missing), multiple
imputation methodology was applied to the data, using
gender and baseline SF-6D values as predictors. For the re-
source use data, multiple imputation methodology was ap-
plied, using gender as a predictor. The inclusion of gender
as a predictor is justified, as the trial was stratified by gen-
der, and availability of data at six months was dependent
on gender, with more males reporting at six month
(73.5%) compared to females (58.7%; Fisher’s Exact Test
p = 0.005). Data on SF-6D, resource use and cost were
analysed using the independent samples Mann–Whitney
U test. Statistical significance was determined using




The flow of the participants and detailed baseline cha-
racteristics have been previously published [16]. A sum-
mary of the patient baseline characteristics is presented
in Table 1, and as can be observed, characteristics were
similar between the HC and UC group.
Overall, 83% of all participants randomised to receive
HC received at least 5 of 10 possible telephone sessions.
The median number of sessions was 8 (range 0–10) and
the mean (SD) call length was 26 (9.3) minutes.
Health status
Using the SF-6D, there were no statistically significant dif-
ferences in baseline health status or utility between the
HC and UC groups (Table 2). At six months, SF-6D data
was available for 141/215 (65.6%) of the HC group and
153/215 (71.2%) of the UC group (See Web Appendix
Additional file 1: Table S2). Using multiple imputation an
increase in health utility was observed in both groups
[HC: 0.130 (95% CI: 0.111 to 0.149); UC: 0.118 (95% CI:






Age, year 61.3 (11.3) 59.9 (11.1) 0.212
Male,% 75.8% 73.5% 0.579
Smoking status
∙ Never smoked 25.1% 30.2% 0.398
∙ Previous smoker 43.7% 38.1%
∙ Current smoker 31.1% 31.6%
Doctor visits in last
six months
4.55 (4.18) 4.79 (4.24) 0.588
Number of times admitted to
hospital in last six months
1.99 (0.95) 1.97 (0.95) 0.840between the two groups (p = 0.372). At 12 months, no sta-
tistically significant further improvement in SF-6D was
observed in either group, resulting in an incremental from
baseline of 0.132 (95% CI: 0.110 to 0.153) for HC and
0.120 (95% CI: 0.098 to 0.142) for UC. Analyses using
completed cases only resulted in similar results (See Web
Appendix Additional file 1: Table S3).
Health care utilisation
The main difference in health care utilisation was that
HC participants were statistically significantly more
likely to be hospitalised compared to UC patients
(Table 3). ‘This difference was mainly due to non-cardio-
vascular hospitalisations’. The main non-cardiovascular
hospitalisations for patients in the HC group were urin-
ary and renal disease (including dialysis), cancer, and
gastric disorders, while for the education group the main
non-cardiovascular hospitalisations and costs were for
urinary and renal disease (including dialysis) and cancer
(data not provided). A similar pattern was observed
when the analysis was performed for completed cases
only (See Web Appendix Additional file 1: Table S4).
Costs
The major difference in costs between the two groups was
the cost for hospitalisation due to causes not related to
MI, angina or chronic heart failure (p = 0.0043), resulting
in higher hospitalisation ($6,841 vs. $4,984, p = 0.036) and
total treatment cost ($10,574 versus $8,534, p = 0.021) for
patients randomised to receive HC versus UC. Analyses
using completed cases only did not result in statistically
significant higher costs for HC compared to UC ($9,677
versus $7,152, p = 0.124).
Cost effectiveness
Within the six-months trial duration, the incremental
cost was $2,040 and the incremental effectiveness was
0.012 QALYs (95% CI: -0.016 to 0.040). The incremental
cost-effectiveness ratio (ICER) of HC compared to UC for
patients with a recent MI was $85,423/QALY (95% CI:
$25,327, dominated).
Discussion
As patients with CHD have a high risk of a secondary
event, there is a need for effective secondary prevention
interventions with good uptake. This study examined the
cost-effectiveness of a novel telephone-delivered second-
ary prevention program for MI patients. We found a sig-
nificant improvement in health status as assessed with the
SF-6D in both the HC and UC groups at six and
12 months, although the difference between groups was
not significant. The intervention was also associated with
higher costs compared to UC. This higher cost was mainly
driven by higher non-cardiovascular hospitalisation (e.g.









Baseline 0.680 (0.009) 0.675 (0.009) 0.005 (−0.021, 0.031) 0.739
Change from baseline - 6 monthsb 0.130 (0.010) 0.118 (0.011) 0.012 (−0.016, 0.041) 0.372
Change from baseline - 12 monthsb 0.132 (0.011) 0.120 (0.011) 0.011 (−0.028, 0.051) 0.738
a Using multiple imputation techniques where gender was used as a predictor.
b Adjusted for baseline value.
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gastric disorders) rather than the costs of running the
intervention.
The primary outcomes paper reported that the inter-
vention resulted in a significant positive effect on mental
HRQoL, as well as Social Functioning and Role Emo-
tional subscales of the SF-36 compared with UC [16].
Patients were also more likely to meet recommended
levels of physical activity, BMI, vegetable intake and al-
cohol consumption. Using the SF-6D summary score, we
did not observe an intervention effect on utility at 6 or
12 months. This could be a result of the fact that pa-
tients in the HC group had numerically lower scores for
physical HRQoL, which may result in no differences on
an overall score. It should be noted that UK weights
were used for the SF-6D, as no Australian weights are
available.Table 3 Utilisation and cost of health care services for health
Utilisation
Mean (se) HC UC p
N 215 215
Health coach sessions 7.2 (0.2)
General Practitioner visits 11.2 (0.4) 11.8 (0.3)
Specialist visits 1.6 (0.2) 1.1 (0.1)
Other health professionals 2.2 (0.3) 1.6 (0.2)
Health services 4.8 (0.4) 5.1 (0.5)
Medication
∙ Cardiac system 2.4 (0.1) 2.5 (0.1)
∙ Lipid modifying drugs 0.8 (0.0) 0.9 (0.1)
∙ Antithrombotic agents 1.6 (0.0) 1.7 (0.0)
∙ Drugs used in diabetes 0.4 (0.0) 0.4 (0.0)
∙ Other medicines 1.4 (0.1) 1.3 (0.1)
Hospital admittance/patient
∙ MI/angina/CHF 0.6 (0.1) 0.5 (0.1)
∙ Other causes 0.9 (0.5) 0.2 (0.1)
∙ Total 1.5 (0.5) 0.7 (0.1)
Total cost
a Using multiple imputation techniques where gender was used as a predictor.
MI, myocardial infarction; CHF, chronic heart failure.There is very limited data available on the cost-
effectiveness of telephone intervention programs as a
secondary intervention for patients with following MI.
Telephone delivered interventions consist of telephone
calls from a health professional who provides health ad-
vice (coaching) to encourage and support behavioural
changes. In contrast, telemonitoring programs involve
patients using monitoring devices to measure certain
clinical parameters (e.g. blood glucose levels) of which
the results are then transmitted by telephone to the
health provider. As such telemonitoring programs are
not easily comparable with programs focusing more on
behavioural changes (i.e. telephone delivered interven-
tions). A recent Cochrane review included structured
telephone interviews or telemonitoring for patients with
chronic heart failure, with the latter being less relevant
[4]. Nine studies included costing of structuredcoaching (HC) and usual care (HC) groups a
Cost
-value HC UC p-value
215 215
N/A $267 ($7) - N/A
0.188 $446 ($14) $470 ($14) 0.188
0.004 $88 ($7) $61 ($5) 0.004
0.048 $104 ($10) $81 ($8) 0.048
0.815 $1,161 ($101) $1,222 ($119) 0.798
0.414 $312 ($16) $329 ($16) 0.328
0.486 $474 ($17) $492 ($16) 0.616
0.462 $385 ($14) $394 ($15) 0.593
0.365 $191 ($29) $169 ($27) 0.419
0.593 $305 ($26) $332 ($52) 0.536
0.240 $4,714 ($641) $4,139 ($771) 0.240
0.054 $2,127 ($558) $846 ($214) 0.043
0.042 $6,841 ($838) $4,984 ($802) 0.036
$10,574 ($855) $8,534 ($813) 0.021
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available for those studies was limited, with often only
information on the cost of the program. As our program
was undertaken by a health coach, the costs of each ses-
sion is relatively low, compared to fully integrated
telehealth programs. The cost of the health coaching
sessions ($37 per session) accounted for less that 4% of
the overall cost for the HC group.
The increased cost for hospitalisation due to causes
other than CHD events in the HC group could be due
to better education, support and monitoring in this
group which may have lead to seeking medical interven-
tion earlier in a disease process. This could potentially
result in cost-savings in the longer term. As we have
analysed health care utilisation at six months, the longer
term health care utilisation and costs is unclear.
Telephonic disease management was not effective and
was not cost-effective in a randomised trial of patients
with systolic or diastolic heart failure over 18 months
[21]. That program improved overall survival; however,
the disease management program was costly and did not
reduce health service utilisation. Telephone delivered
intervention for physical activity and diet in a group of
adults with chronic disease was considered cost-effective
at an ICER of $12,153/QALY for telephone counselling
compared to real-life care [14]; however that study used
a theoretical UC group instead of the group of
randomised controls [14]. In another clinical trial com-
paring telephone counselling with UC reported an ICER
of $78,489/QALY [22]. Other telephone-intervention
studies have reported cost-savings from reduced re-
admission rates, reduced length of stay [23] whereas an-
other study reported an unacceptably high cost per
QALY gained of $146,870 [21]. The large variance in
cost-effectiveness results has provided impetus, in part,
for a large-scale telephone intervention study of health
coaching with >45,000 patients [24].
In the present study there were losses to follow-up
and incomplete data; therefore multiple imputation tech-
niques were applied. For hospitalisation rates and costs,
data was available for all patients. Therefore, a compari-
son for the number of hospitalisations between the com-
pleted cases and multiple imputation analyses (including
all patients) can give an indication of the health of the
patients who completed and did not complete the six-
month follow-up. Patients who continued follow-up had
fewer hospitalisations compared to patients who had
missing health services data. No differences in HRQoL
were observed between patients with and without miss-
ing data, using multiple imputation techniques. While
missing data is potentially a limitation of the study, hos-
pitalisation data in public hospitals was available for all
patients randomised in the study and the hospitalisation
costs accounted for the majority of the difference in costbetween the two treatment groups (91% for multiple im-
putation analysis).
This analysis relied upon self-reported patient data;
this leads to some uncertainty around the accuracy of
the data. Self-reporting can underestimate the number
of GP visits using longer recall periods (one year) com-
pared to one month recall period [25]. We performed an
analysis on a subsample of 10% to check patient
reported data with claims made by their physician. There
was significant underreporting for the six month recall
period; however, there was a reasonable correlation be-
tween number of reported GP visits and claims made by
their GP. As such, linear regression methodology was
applied. As we could not verify the self-reported data for
visits to specialists, other health professionals, health
services and medication use with claims data, the self-
reported data has been used without any modification. It
is uncertain whether the use of self-reported data would
bias the results in favour of health coaching. Hospitalisa-
tion data for each patient was available for all public
hospital admissions in Queensland; however, some pa-
tients reported an admission to hospital in a private
hospitals or public hospitals in a different state. Self-
reported admission to private hospitals was not different
between the two study groups, and therefore no adjust-
ments were performed.
Conclusions
ProActive Heart, a telephone delivered CHD secondary
prevention program, was not a cost-effective interven-
tion in the short-term compared to UC. There was no
significant improvement in utility and it resulted in sig-
nificantly increased costs. However, while we have not
assessed this in the current study, higher cost may result
in future cost-savings as patients are potentially better
monitored, and therefore it could be suggested that
health problems may be identified at an earlier stage
resulting in better health outcomes.
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